Inhibition of enhancer of zest homologue 2 is a potential therapeutic target for high‐MYC medulloblastoma
Manabu Natsumeda(Niigata University), Charles G. Eberhart(The University of Texas MD Anderson Cancer Center), Allison R. Hanaford(Johns Hopkins Medicine), Eric H. Raabe(Johns Hopkins University), Sama Ahsan(Johns Hopkins Hospital), Hiroaki Miyahara(Aichi Medical University), Duncan Stearns(Rainbow Babies & Children's Hospital), Yang Liu(TU Dortmund University), Fausto J. Rodríguez(Unknown), Ulf D. Kahlert(Düsseldorf University Hospital), Nicolas Skuli(Centre de Recherche en Cancérologie de Toulouse), Satoshi Nakata(Johns Hopkins University)
Cited by 11
Related Papers
Medulloblastoma Comprises Four Distinct Molecular Variants
|Journal of Clinical Oncology|2010|1.4k
Intertumoral Heterogeneity within Medulloblastoma Subgroups
|Cancer Cell|2017|1.3k
Altered Telomeres in Tumors with <i>ATRX</i> and <i>DAXX</i> Mutations
|Science|2011|1.1k
Comprehensive Analysis of Hypermutation in Human Cancer
|Cell|2017|795
Functionally defined therapeutic targets in diffuse intrinsic pontine glioma
|Nature Medicine|2015|711